All In Biotech

Drugs by condition

Drugs approved for paroxysmal nocturnal hemoglobinuria

Brand-name prescription drugs and biologics whose FDA label lists paroxysmal nocturnal hemoglobinuria as an approved use. Matched on the label phrases: "paroxysmal nocturnal hemoglobinuria".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

8

Still marketed, NDA or BLA

Drug classes

4

Novel drugs

6

New molecular entities and new biologics

In development

13

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for paroxysmal nocturnal hemoglobinuria.

  • Epysqli (Eculizumab-Aagh) · Samsung Bioepis CO LTD Jul 19, 2024
  • Piasky (Crovalimab-Akkz) · Genentech INC NovelOrphanJun 20, 2024
  • Bkemv (Eculizumab-Aeeb) · Amgen INC May 28, 2024
  • Voydeya (Danicopan) · Alexion Pharms INC NovelBreakthrough therapyOrphanMar 29, 2024
  • Fabhalta (Iptacopan Hydrochloride) · Novartis NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanDec 5, 2023

All approved drugs for paroxysmal nocturnal hemoglobinuria, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Complement Inhibitor (5)

  • Empaveli Pegcetacoplan · Apellis Pharms · 2021
  • Ultomiris Ravulizumab-Cwvz · Alexion Pharm · 2018
  • Soliris Eculizumab · Alexion Pharm · 2007
  • Epysqli Eculizumab-Aagh · Samsung Bioepis CO LTD · 2024
  • Bkemv Eculizumab-Aeeb · Amgen INC · 2024

Complement C5 Inhibitor (1)

  • Piasky Crovalimab-Akkz · Genentech INC · 2024

Complement Factor D Inhibitor (1)

  • Voydeya Danicopan · Alexion Pharms INC · 2024

Class not listed in FDA's data (1)

  • Fabhalta Iptacopan Hydrochloride · Novartis · 2023

Drugs in development for paroxysmal nocturnal hemoglobinuria

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • HRS-5965Phase 36 trials

    Chengdu Suncadia Medicine Co., Ltd. · Primary IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria

  • CemdisiranALN-CC5Phase 35 trials

    Regeneron · Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, Age-related Macular Degeneration (AMD)

  • HSK39297Phase 35 trials

    Haisco Pharmaceutical Group Co., Ltd. · IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Haemoglobinuria (PNH)

  • MY008211APhase 35 trials

    Wuhan Createrna Science and Technology Co., Ltd · Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN)

  • FXS6837Phase 34 trials

    Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Paroxysmal Nocturnal Hemoglobinuria, Primary IgAN, IgAN

  • NTQ5082Phase 34 trials

    Nanjing Chia-tai Tianqing Pharmaceutical · Paroxysmal Nocturnal Hemoglobinuria, Primary IgA Nephropathy

  • VSA012Phase 31 trial

    Bisirna Therapeutics (Suzhou) Co., Ltd. · Paroxysmal Nocturnal Hemoglobinuria, PNH

  • NM8074Phase 28 trials

    NovelMed Therapeutics · Paroxysmal Nocturnal Hemoglobinuria, Dermatomyositis, PNH - Paroxysmal Nocturnal Hemoglobinuria

  • LP-005Phase 24 trials

    Longbio Pharma · Periodontitis, Paroxysmal Nocturnal Hemoglobinuria, Complement-mediated Renal Diseases

  • HS-10542Phase 22 trials

    Jiangsu Hansoh Pharmaceutical Co., Ltd. · IgAN, Immunoglobulin A Nephropathy (IgAN), Glomerular Disease

  • SGB-9768Phase 22 trials

    Suzhou Sanegene Bio Inc. · PNH - Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy (IgAN), C3 Glomerulopathy

  • SLN12140Phase 22 trials

    Linno Pharmaceuticals, Inc. · IgA Nephropathy (IgAN), Paroxysmal Nocturnal Hemoglobinuria (PNH)

  • XH-S003Phase 22 trials

    Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · PNH - Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy

More on paroxysmal nocturnal hemoglobinuria: recruiting trials · published research

Related in hematology and blood cancers: Multiple myeloma · Acute myeloid leukemia · Chronic lymphocytic leukemia · Acute lymphoblastic leukemia · Chronic myeloid leukemia · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Myelodysplastic syndromes · Myelofibrosis · Sickle cell disease

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.